Versican G1 and G3 domains are upregulated and latent transforming growth factor-β binding protein-4 is downregulated in breast cancer stroma

Breast Cancer

Volumn 19, Issue 1, 2012, Pages 46-53

  Takahashi, Yuko ^a   Kuwabara, Hiroko ^a   Yoneda, Masahiko ^b   Isogai, Zenzo ^c   Tanigawa, Nobuhiko ^a   Shibayama, Yuro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b AICHI PREFECTURAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Biomarker; Breast cancer; Hyaluronan; Latent transforming growth factor binding protein 1; Versican

Indexed keywords

FIBRILLIN; KI 67 ANTIGEN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 4; MESSENGER RNA; UNCLASSIFIED DRUG; VERSICAN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

EID: 85027924926     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0264-7     Document Type: Article

References (32)

1. Kimata K, Oike Y, Tani K, Shinomura T, Yamagata M, Uritani M, et al. A large chondroitin sulfate proteoglycan (PG-M) synthesized before chondrogenesis in the limb bud of chick embryo. J Biol Chem. 1986;261:13517-25. (Pubitemid 17196369)
2. Ito K, Shinomura T, Zako M, Ujita M, Kimata K. Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycan generated by alternative splicing. J Biol Chem. 1995;270:958-65.
3. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617-23. (Pubitemid 35247746)
4. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronan binding properties of versican. J Biol Chem. 1992;267:10003-10.
5. Isogai Z, Aspberg A, Kneene DR, Ono RN, Reinhardt DP, Sakai LY. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem. 2002;277:4565-72. (Pubitemid 34968726)
6. Proia DA, Kuperwasser C. Stroma. Tumor agonist or antagonist. Cell Cycle. 2005;4:1022-5.
7. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol. 2008;18:288-95.
8. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009;28:233-45.
9. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment. possible involvement of versican/PG-M. Am J Pathol. 2007;170:1086-99. (Pubitemid 47339375)
10. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
11. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation. Crit Rev Clin Lab Sci. 2004;41:233-64. (Pubitemid 38888060)
12. Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, et al. Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors. Proc Natl Acad Sci USA. 2008;105:18758-63.
13. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor β-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003;278:2750-7. (Pubitemid 36801356)
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-9. (Pubitemid 17064313)
15. Zhao X, Russell P. Versican splice variants in human trabecular meshwork and ciliary muscle. Mol Vis. 2005;11:603-8. (Pubitemid 41410215)
16. Hasegawa K, Yoneda M, Kuwabara H, Miyaishi O, Itano N, Ohno A, et al. Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding ability in solar elastosis. J Invest Dermatol. 2007;127:1657-63. (Pubitemid 46933404)
17. Ohno-Jinno A, Isogai Z, Yoneda M, Kasai K, Miyaishi O, Inoue Y, et al. Versican and fibrillin-1 form a major hyaluronan-binding complex in the ciliary body. Invest Ophthalmol Vis Sci. 2008;49:2870-7.
18. Isogai Z, Shinomura T, Yamakawa N, Takeuchi J, Tsuji T, Heinegard D, et al. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res. 1996;56:3902-8. (Pubitemid 26284737)
19. Green SJ, Tarone G, Underhill CB. Distribution of hyaluronate and hyaluronate receptors in the adult lung. J Cell Sci. 1998;90:145-56.
20. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PAE, Harris AL, et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res. 2000;6:4278-86.
21. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell. 2005;16:1330-40. (Pubitemid 40349568)
22. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer. 2010;126:640-50.
23. Yang BL, Zhang Y, Cao L, Yang BB. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem. 1999;72:210-20. (Pubitemid 29021934)
24. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, et al. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol. 1999;58:597-605. (Pubitemid 29264939)
25. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, et al. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007;9:R47.
26. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004;18:754-6.
27. Bhardwaj A, Frankel WL, Pellegata NS, Wen P, Prasad ML. Intracellular versican expression in mesenchymal spindle cell tumors contrasts with extracellular expression in epithelial and other tumors - a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2008;16:263-6. (Pubitemid 351589549)
28. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumor-microenvironment interactions. Hum Mol Genet. 2001;10:1907-13. (Pubitemid 32910535)
29. Mauel S, Kruse B, Etschmann B, von der Schulenburg AG, Schaerig M, Stovesand K, et al. Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo. APMIS. 2007;115:687-700. (Pubitemid 46854982)
30. Sterner-Kock A, Thorey IS, Koli K, Wempe F, Otte J, Bangsow T, et al. Disruption of the gene encoding the latent transforming growth factor-β binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev. 2002;16:2264-73. (Pubitemid 35013089)
31. Roth-Eichhorn S, Heitmann B, Flemming P, Kubicka S, Trautwein C. Evidence for the decreased expression of the latent TGF-β binding protein and its splice form in human liver tumours. Scand J Gastroenterol. 2001;11:1204-10. (Pubitemid 32917591)
32. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010;277:3904-23.